Related Experiment Video
Updated: Aug 29, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
[Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma]
Xiao-dong Cheng1, Wei-guo Lü, Xing Xie
1Department of Gynecological Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Objective:
To analysis the related factors of efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma.
Methods:
Forty-one patients with platinum-sensitive recurrent ovarian cancer from Jan. 1998 to Oct. 2002 were reviewed, 37 factors were analyzed, including age, the optimal of primary surgery, number of chemotherapy cycles, standard chemotherapy or not, serum CA(125) level, follow up or not, relapse interval, the site and the number of relapse lesion, et al.
Results:
Response rate of chemotherapy was 56%, the toxicity was not serious. Response rate of standard chemotherapy was 76% (19/25), not standard chemotherapy was 25% (4/16), standard chemotherapy or not was the only factor related to efficacy (P < 0.05).
Conclusion:
Re-platinum chemotherapy to platinum-sensitive recurrent ovarian carcinoma is reasonable, standard chemotherapy or not affects the response rate.
